1.Emergency Total Arch Replacement with J-Graft Open Stent Graft for Acute Type A Aortic Dissection, Requiring TEVAR for Stent Graft Stenosis
Hidetaka Wakiyama ; Hidefumi Obo ; Sou Izumi ; Kyouzou Inoue ; Noboru Wakita
Japanese Journal of Cardiovascular Surgery 2017;46(1):39-44
A 76-year-old man was admitted to our hospital to receive optimal medical therapy for acute type B aortic dissection with a thrombosed false lumen. Eighteen days after admission, computed tomography (CT) was performed because of back pain and showed new retrograde acute type A aortic dissection. Emergency total arch replacement was performed with the aid of a J-graft open stent graft (JOSG). Postoperatively, the blood pressure in the lower extremities decreased to 70% of systemic blood pressure without symptoms. Enhanced CT showed severe stenosis from the non-stent part of the aorta to the proximal part of the JOSG. On postoperative day 2, thoracic endovascular aortic repair (TEVAR) was performed for stent graft stenosis. The blood pressure of the lower extremities promptly recovered after the procedure, and the patient was extubated without any neurologic deficits on the next day. Postoperative CT demonstrated that the stent graft stenosis had been effectively alleviated. The patient's subsequent course was uneventful and he was discharged on postoperative day 24.
A JOSG should only be deployed after precise evaluation of the anatomy of the target aorta and careful attention should be paid to the length of the non-stent part of the graft in order to prevent unpredictable graft retraction that could cause stent graft stenosis. TEVAR is considered to be a good option to treat complications related to open stent grafts.
2.Hyperbaric Oxygen Treatment of Carbon Monoxide Poisoning in the Past 5 Years
Kenji NAKAMAE ; Yoshiyuki HYODO ; Yoshikazu NARA ; Hirotaka INOUE ; Masayuki OKIJIMA ; Masahiro OGAWA ; Koji KONDO ; Yuki FUJII ; Atsuya SAKAIDE ; Kazuyoshi NISHIYAMA ; Ryota TANI ; Izumi OTA ; Osamu KAWAGUCHI
Journal of the Japanese Association of Rural Medicine 2016;65(1):1-8
Hyperbaric oxygen (HBO) therapy for acute carbon monoxide (CO) poisoning is performed after oxygen therapy and breathing therapy. The usefulness of HBO therapy in emergency treatment has been reported. In this study, we examined the effectiveness of HBO for CO poisoning that was performed at our hospital over the past 5 years. Subjects were 23 patients who had HBO therapy for CO poisoning in the period January 2008-November 2013. The male to female ratio of the cases was 14:9 and the mean age was 54.6±20.8 years. The cause was suicide in 39.1% of cases and accident in 60.9%. The mean number of treatments was 5.4±6.8. The atmosphere absolute was 2ATA:2.8ATA=12:11. The ratio of direct conveyance of the patient to our hospital to indirect conveyance of the patient from another hospital was 15:8. The effectiveness of HBO therapy at the time of discharge was 73.9%. However, delayed neuropsychiatric sequelae (DNS) was detected in 3 of the 23 cases of CO poisoning. No correlations were found between elapsed time after CO inhalation and various blood parameters. However, time to start of therapy is important for DNS, and our results suggest that early treatment at a hospital with a hyperbaric chamber is necessary.
3.Relationship between Treatment Choices according to the Modified Osteoporotic Fracture Score and Posttreatment Radiographic Outcomes
Shinya TOKUNAGA ; Toshiyuki TAKAHASHI ; Koki MITANI ; Tomoo INOUE ; Ryo KANEMATSU ; Manabu MINAMI ; Izumi SUDA ; Sho NAKAMURA ; Junya HANAKITA
Asian Spine Journal 2024;18(2):251-259
Methods:
Consecutive patients diagnosed with OFs at Fujieda Heisei Memorial Hospital were divided into three groups: nonsurgical therapy, balloon kyphoplasty (BKP), and open surgery groups. The mOF score was calculated, and the levels of independence and posttreatment imaging data were compared between patients treated and not treated according to the mOF score-based treatment recommendation.
Results:
In total, 118 patients were included (nonsurgical therapy, n=57; BKP, n=48; open surgery, n=13), of whom 100 (85%) received treatment consistent with the mOF score-based treatment recommendation. In the BKP and open surgery groups, the mOF scorebased treatment recommendations were consistent with the actual treatment in 93% of the patients. However, in the nonsurgical group, the mOF score-based treatment recommendation was not consistent with the actual treatment in 25% of the patients. In this group, patients not treated according to the mOF score had significantly shorter vertebral body height, greater local kyphosis, and smaller sacral slope after treatment than patients treated according to the mOF score-based treatment recommendation.
Conclusions
In the BKP and open surgery groups, the mOF scores were consistent with actual clinical selection. In the nonsurgical therapy group, patients not treated according to the mOF score-based treatment recommendation exhibited severe vertebral body deformity and a less well-balanced spine shape after treatment. The mOF score may help in selecting suitable treatments for OFs.
4.Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus.
Hideyuki TAMAI ; Naoki SHINGAKI ; Yoshiyuki MORI ; Kosaku MORIBATA ; Akira KAWASHIMA ; Yoshimasa MAEDA ; Toru NIWA ; Hisanobu DEGUCHI ; Izumi INOUE ; Takao MAEKITA ; Mikitaka IGUCHI ; Jun KATO ; Masao ICHINOSE
Gut and Liver 2016;10(4):617-623
BACKGROUND/AIMS: This study aimed to predict sustained viral response (SVR) to low-dose pegylated interferon (PEG-IFN) plus ribavirin of elderly and/or cirrhotic patients with genotype 2 hepatitis C virus (HCV) using viral response within 2 weeks. METHODS: Low-dose PEG-IFN-α-2b plus ribavirin was administered to 50 elderly and/or cirrhotic patients with genotype 2 HCV for 24 weeks. The dynamics of HCV RNA and HCV core antigen levels within 2 weeks were measured. RESULTS: The patients' median age was 66 years. There were 21 male and 29 female patients. The median baseline HCV RNA level was 5.7 log IU/mL. Rapid viral response was achieved in 17 patients (34%), SVR in 28 (56%), and two (4%) discontinued treatment. Univariate analysis of factors contributing to SVR showed significant differences for sex, baseline virus level, and response within 4 weeks. When 40 fmol/L was set as the cutoff value for the core antigen level at 1 week, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for predicting SVR were 93%, 75%, 84%, 88%, and 85%, respectively. CONCLUSIONS: Low-dose PEG-IFN plus ribavirin was a safe and cost-effective treatment for elderly and/or cirrhotic patients with genotype 2 HCV, and the viral response within 2 weeks was a useful predictor of SVR.
Aged*
;
Female
;
Genotype*
;
Hepacivirus*
;
Hepatitis C*
;
Hepatitis*
;
Humans
;
Interferons*
;
Liver Cirrhosis
;
Male
;
Ribavirin*
;
RNA
;
Sensitivity and Specificity
5.Prediction of a Null Response to Pegylated Interferon alpha-2b Plus Ribavirin in Patients with High Viral Load Genotype 1b Hepatitis C.
Yuki WADA ; Hideyuki TAMAI ; Akira KAWASHIMA ; Naoki SHINGAKI ; Yoshiyuki MORI ; Masanori KAWAGUCHI ; Kosaku MORIBATA ; Hisanobu DEGUCHI ; Kazuki UEDA ; Izumi INOUE ; Takao MAEKITA ; Mikitaka IGUCHI ; Jun KATO ; Masao ICHINOSE
Gut and Liver 2014;8(4):421-427
BACKGROUND/AIMS: The present study aimed to clarify whether virological response within 2 weeks after therapy initiation can predict a null response to pegylated interferon alpha-2b plus ribavirin therapy in patients with high viral load genotype 1b hepatitis C. METHODS: The participants consisted of 72 patients with high viral load genotype 1b. The dynamics of viral load within 2 weeks were measured. RESULTS: Significant differences between null responders and nonnull responders were noted for interleukin (IL)-28B genotype, amino acid 70 substitution, alpha-fetoprotein, low-density lipoprotein cholesterol, hyaluronic acid, and viral response. The area under the curve (AUC) for the receiver operating characteristic curve of the hepatitis C virus (HCV) RNA level decline at 2 weeks (AUC=0.993) was the highest among the factors predicting the null response. When the cutoff value for the HCV RNA level decline at 2 weeks was set at 0.80 log, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy in predicting a null response were 82%, 96%, 82%, 96%, and 94%, respectively. In comparison, values for the non-TT and mutant type of amino acid 70 substitution were similar to those for HCV RNA level decline at 2 weeks. CONCLUSIONS: Virological response at 2 weeks or the combination of IL-28B and amino acid 70 substitution are accurate predictors of a null response.
Administration, Oral
;
Adult
;
Aged
;
Antiviral Agents/*administration & dosage
;
Area Under Curve
;
Drug Therapy, Combination
;
Female
;
Genotype
;
Hepatitis C, Chronic/*drug therapy/genetics
;
Humans
;
Injections, Subcutaneous
;
Interferon-alpha/*administration & dosage
;
Male
;
Medication Adherence
;
Polyethylene Glycols/*administration & dosage
;
Prospective Studies
;
RNA, Viral/metabolism
;
Recombinant Proteins/administration & dosage
;
Ribavirin/*administration & dosage
;
Treatment Outcome
;
Viral Load
;
Young Adult
6.A Case of Brugada Syndrome Treated With Percutaneous Epicardial Catheter Ablation
Masahiro OGAWA ; Yoshiyuki HYOUDOU ; Masayuki OKIJIMA ; Hirotaka INOUE ; Kouji KONDOU ; Yuki FUJII ; Atsuya SAKAIDE ; Keisuke TSUJIKAWA ; Kazuyoshi NISHIYAMA ; Ryouta TANI ; Izumi OHTA ; Mizuki ENDOU ; Kimitoshi SANO ; Kenji NAKAMAE ; Shinji KANEKO ; Masaya FUJITA ; Yousuke TATAMI ; Osamu KAWAGUCHI
Journal of the Japanese Association of Rural Medicine 2020;69(4):385-
This case report describes our first experience performing percutaneous epicardial catheter ablation for Burugada syndrome in our hospital. We describe the good results achieved in this case. The patient was a man in his 30s with no remarkable medical history. However, his family history was notable for the sudden death of his grandfather at age 37 years and his father at age 27 years. While asleep, the patient experienced convulsions and lost consciousness. During emergency transportation, defibrillation was performed 7 times by the ambulance crew. When the patient arrived at our hospital, sinus rhythm was observed on ECG. During resuscitation, Burugada syndrome was diagnosed based on ECG findings. On hospital day 6, an internal cardioverter defibrillator was implanted. After discharge, the defibrillator operated 10 times, so we opted for ablation treatment. Fractionated potential of over 150 ms was confirmed in the right ventricular outflow tract. A low voltage zone of <1 mV could be mapped, and the same site was cauterized a total of 46 times. As a result, ST segment amplitude decreased significantly in lead V1 on ECG. Percutaneous epicardial catheter ablation performed with reference to Nademanee’s report achieved good results in this case of Burugada syndrome.